CARDINAL HEALTH INC（CAH）の決算・業績分析
CARDINAL HEALTH INCの2025年有価証券報告書をAI分析。売上高$222.6B(-1.9%)。営業利益$2.3B。Industrials。
目次
CARDINAL HEALTH INCの2025年度 業績サマリー
CARDINAL HEALTH INC（証券コード: CAH）の2025年度決算・業績分析。売上高は$222.6B（前年比-1.9%）。営業利益は$2.3B（前年比+83.0%）。純利益は$1.6B（前年比+83.2%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
CARDINAL HEALTH INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged 11.6% YoY to $181.3B (XBRL), but operating income plummeted 228.6% YoY to -$607M (XBRL) and net income collapsed 253.5% YoY to -$938M (XBRL).
- Despite a 3.6% gross margin (XBRL), the company reported a -0.3% operating margin (XBRL) and -0.5% net margin (XBRL), signaling severe profitability challenges.
- Shareholders received $1.6B in total returns (dividends + buybacks) (XBRL), but equity fell to -6.8% (XBRL) and total assets declined to $43.3B (XBRL) in FY2024.
CARDINAL HEALTH INCの売上高変化の要因
- •Total revenue grew 11.6% YoY to $181.3B (XBRL), reflecting a 5-year CAGR of 8.4% (XBRL). However, segment-specific revenue drivers are not available in the data (XBRL). Historical revenue growth accelerated from $136.8B in FY2020 to $181.3B in FY2024, with a notable dip in FY2022 (-4.1B operating income) before rebounding in FY2023 (472M) and FY2024 (-607M).
CARDINAL HEALTH INCの営業利益変化の要因
- •Profitability metrics deteriorated sharply: gross profit of $6.5B (3.6% margin) (XBRL) was offset by a -$607M operating income (-0.3% margin) (XBRL) and -$938M net income (-0.5% margin) (XBRL). YoY comparisons show operating income fell 228.6% and net income dropped 253.5% (XBRL). The 5-year CAGR for operating income was +42.9% (XBRL), but this trend reversed in FY2024. Cost structure details (e.g., SG&A, R&D) are not quantified (XBRL).
CARDINAL HEALTH INCの事業内容
Cardinal Health Inc (CAH) operates in the healthcare industry, focusing on pharmaceutical and medical products distribution. The company restructured into two reportable segments in FY2024: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD) (10-K). While the business model centers on supply chain solutions and product distribution, segment-specific revenue or operating income data is not quantified in the provided data (XBRL). The company competes in a highly regulated industry with significant capital intensity (0.2% CapEx intensity) (XBRL).
CARDINAL HEALTH INCのAI業績分析レポート（2024年度）
Cardinal Health Inc (CAH) FY2024 Annual Report Analysis
Highlights
Business Overview
Cardinal Health Inc (CAH) operates in the healthcare industry, focusing on pharmaceutical and medical products distribution. The company restructured into two reportable segments in FY2024: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD) (10-K). While the business model centers on supply chain solutions and product distribution, segment-specific revenue or operating income data is not quantified in the data (XBRL). The company competes in a highly regulated industry with significant capital intensity (0.2% CapEx intensity) (XBRL).
Revenue Analysis
Total revenue grew 11.6% YoY to $181.3B (XBRL), reflecting a 5-year CAGR of 8.4% (XBRL). However, segment-specific revenue drivers are not available in the data (XBRL). Historical revenue growth accelerated from $136.8B in FY2020 to $181.3B in FY2024, with a notable dip in FY2022 (-4.1B operating income) before rebounding in FY2023 (472M) and FY2024 (-607M).
Profitability Analysis
Profitability metrics deteriorated sharply: gross profit of $6.5B (3.6% margin) (XBRL) was offset by a -$607M operating income (-0.3% margin) (XBRL) and -$938M net income (-0.5% margin) (XBRL). YoY comparisons show operating income fell 228.6% and net income dropped 253.5% (XBRL). The 5-year CAGR for operating income was +42.9% (XBRL), but this trend reversed in FY2024. Cost structure details (e.g., SG&A, R&D) are not quantified (XBRL).
Balance Sheet Analysis
Total assets declined to $43.3B (XBRL) in FY2024, while total equity fell to -6.8% (XBRL). Cash reserves stood at $4.1B (XBRL). The current ratio remained stable at 1.00x (XBRL), but liquidity details (credit facilities) are not disclosed (XBRL). Total debt levels and maturity profiles are not quantified (XBRL).
Cash Flow Analysis
Operating cash flow increased to $3.2B (XBRL), generating $2.8B free cash flow (FCF) after $387M CapEx (XBRL). Shareholders received $559M in dividends and $1.0B in share repurchases (XBRL). Investing cash flow totaled $567M (XBRL), but no major acquisitions or divestitures are quantified (XBRL). Financing cash flow was -$2.5B (XBRL), driven by dividend payments and buybacks.
Working Capital Analysis
N/A
Risks
N/A
Outlook
N/A
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 136.8B | 145.5B | 152.9B | 162.5B | 181.3B | 205.0B |
| Operating Income | 126M | 2.1B | -4.1B | 472M | -607M | 752M |
| Net Income | 256M | 1.4B | -3.7B | 611M | -938M | 330M |
| Total Assets | 40.0B | 41.0B | 40.8B | 44.5B | 43.3B | 45.1B |
| Total Equity | 6.3B | 1.8B | 1.8B | -709M | -3.0B | -3.2B |
| Operating Cash Flow | 2.8B | 2.7B | 2.0B | 2.4B | 3.2B | 2.8B |
Industrialsの企業一覧
CARDINAL HEALTH INCと同じ「Industrials」セクターの企業